Research programme: RNA therapeutics - Riboxx Pharmaceuticals

Drug Profile

Research programme: RNA therapeutics - Riboxx Pharmaceuticals

Alternative Names: Apoxxim; RGC 1; RGC L1; RGC L2; RGIC 1; RIBOXXIM ®; RIBOXXON®

Latest Information Update: 18 Feb 2016

Price : $50

At a glance

  • Originator Riboxx Pharmaceuticals
  • Developer Riboxx Pharmaceuticals; TOLLYS SAS
  • Class Drug conjugates; RNA
  • Mechanism of Action DDX58 protein modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Autoimmune disorders; Cancer; Viral infections

Highest Development Phases

  • Preclinical Cancer; Viral infections
  • Research Autoimmune disorders

Most Recent Events

  • 18 Feb 2016 RNA therapeutics - Riboxx Pharmaceuticals is available for licensing in World as of 18 Feb 2016. http://www.riboxx-pharma.com/start/home.html
  • 18 Feb 2016 Riboxx Pharmaceuticals has patents pending for Riboxxim® platform in USA and European Union (Riboxx Pharmaceuticals website, February 2016)
  • 18 Feb 2016 Riboxx Pharmaceuticals plans a phase I/IIa trial for Viral infection in Germany (Riboxx Pharmaceuticals website, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top